《JAMA,6月8日,Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-06-09
  • Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
    Elizabeth Whittaker, MD1,2; Alasdair Bamford, MD3,4; Julia Kenny, MD5,6; et alMyrsini Kaforou, PhD2; Christine E. Jones, MD7; Priyen Shah, MD2; Padmanabhan Ramnarayan, MD1,8; Alain Fraisse, MD9; Owen Miller, MD10,11; Patrick Davies, MD12; Filip Kucera, MD13; Joe Brierley, MD14; Marilyn McDougall, MD6,15; Michael Carter, MD6,15; Adriana Tremoulet, MD16; Chisato Shimizu, MD16; Jethro Herberg, MD1,2; Jane C. Burns, MD16; Hermione Lyall, MD1; Michael Levin, MD2; for the PIMS-TS Study Group and EUCLIDS and PERFORM Consortia
    Author Affiliations Article Information
    JAMA. Published online June 8, 2020. doi:10.1001/jama.2020.10369

    Abstract
    Importance  In communities with high rates of coronavirus disease 2019, reports have emerged of children with an unusual syndrome of fever and inflammation.

    Objectives  To describe the clinical and laboratory characteristics of hospitalized children who met criteria for the pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PIMS-TS) and compare these characteristics with other pediatric inflammatory disorders.

    Design, Setting, and Participants  Case series of 58 children from 8 hospitals in England admitted between March 23 and May 16, 2020, with persistent fever and laboratory evidence of inflammation meeting published definitions for PIMS-TS. The final date of follow-up was May 22, 2020. Clinical and laboratory characteristics were abstracted by medical record review, and were compared with clinical characteristics of patients with Kawasaki disease (KD) (n = 1132), KD shock syndrome (n = 45), and toxic shock syndrome (n = 37) who had been admitted to hospitals in Europe and the US from 2002 to 2019.

  • 原文来源:https://jamanetwork.com/journals/jama/fullarticle/2767209
相关报告
  • 《J Pediatrics,6月14日,Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection: A Multi-institutional Study from New York City》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-06-15
    • Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection: A Multi-institutional Study from New York City Author links open overlay panelShubhiKaushikMBBS1∗Scott I.AydinMD12∗Kim R.DerespinaMD3Prerna B.BansalMD2ShannaKowalskyDO4RebeccaTrachtmanMD5Jennifer K.GillenMD1Michelle M.PerezMD3Sara H.SoshnickDO, MS3Edward E.ConwayJr.MD6AsherBercowMD6Howard S.SeidenMD2Robert H.PassMD2Henry M.UshayMD, PhD3GeorgeOfori-AmanfoMD12Shivanand S.MedarMD37 Show more https://doi.org/10.1016/j.jpeds.2020.06.045 Abstract Objective To assess clinical characteristics and outcomes of SARS-CoV-2 associated multisystem inflammatory syndrome in children (MIS-C). Study design Children with MIS-C admitted to pediatric intensive care units (PICU) in New York City between April 23 and May 23, 2020 were included. Demographic and clinical data were collected. Results Of 33 children with MIS-C, the median age was 10 years; 61% were male; 45% were Hispanic/Latino; 39% were black. Comorbidities were present in 45%. Fever (93%) and vomiting (69%) were the most common presenting symptoms. Depressed left ventricular ejection fraction (LVEF) was found in 63% of patients with median EF of 46.6% (IQR 39.5, 52.8). C-reactive protein, procalcitonin, D-dimer, and pro-B-type natriuretic peptide levels were elevated in all patients. For treatment, intravenous immunoglobulin was used in 18 (54%), corticosteroids in 17 (51%), tocilizumab in 12 (36%), remdesivir in 7 (21%), vasopressors in 17 (51%), mechanical ventilation in 5 (15%), extracorporeal membrane oxygenation (ECMO) in 1 (3%), and intra-aortic balloon pump in 1 (3%). The LVEF normalized in 95% of those with depressed EF. All patients were discharged home with median duration of PICU stay of 4.7 (4, 8) days and hospital stay of 7.8 (6, 10.1) days. One (3%) patient died after withdrawal of care secondary to stroke while on ECMO.
  • 《JAMA,6月8日,Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-06-09
    • Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City Eva W. Cheung, MD1; Philip Zachariah, MD, MS1; Mark Gorelik, MD1; et alAlexis Boneparth, MD1; Steven G. Kernie, MD1; Jordan S. Orange, MD, PhD1; Joshua D. Milner, MD1 Author Affiliations Article Information JAMA. Published online June 8, 2020. doi:10.1001/jama.2020.10374 Patients were included if they (1) were 21 years or younger; (2) were hospitalized at Columbia University Irving Medical Center/NewYork-Presbyterian Morgan Stanley Children’s Hospital in New York City between April 18 and May 5, 2020; (3) presented with a clinical syndrome characterized by prolonged fever, systemic inflammation, shock, end-organ dysfunction, or symptoms reminiscent of KD or TSS; and (4) had evidence of recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection was determined by reverse transcriptase–polymerase chain reaction (RT-PCR) of nasopharyngeal swabs or positive serology. Serology testing was done using a New York State Department of Health–approved combined assay for IgM and IgG antibodies against SARS-CoV-2 spike trimer or nucleocapsid protein (96% specificity, 93% sensitivity). Admission testing included hematologic parameters, chemistries, co-infections, and inflammatory markers along with assessments of cardiac function (electrocardiograms, transthoracic echocardiograms). The Columbia University ethics committee approved the study with a waiver of informed consent.